53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.
51 citations
,
January 2003 in “Hormone Research in Paediatrics” This review discusses hormonal influences on hair growth and suggests that understanding hormone-gene interactions may improve treatment of hirsutism and alopecia, but reports no new clinical findings.
48 citations
,
July 2009 in “The Journal of Sexual Medicine” In this study, 50 mg/day of DHEA supplementation in postmenopausal women did not significantly improve sexual function compared to a placebo over 26 weeks.
47 citations
,
November 2012 in “Expert Opinion on Therapeutic Patents” The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.
46 citations
,
May 1986 in “Seminars in Reproductive Medicine” Testosterone and dihydrotestosterone affect hair growth, and new techniques like the folliculogram help study it, but fully understanding hair growth is still complex.
45 citations
,
September 1998 in “Journal of Investigative Dermatology” This study found that sebaceous glands predominantly exhibit oxidative activity of the type 2 17β-hydroxysteroid dehydrogenase isozyme, which is not inhibited by 13-cis retinoic acid.
44 citations
,
March 2004 in “Journal of Investigative Dermatology” This study observed that in vitro treatment of male frontotemporal scalp hair follicles with 17-β-estradiol stimulated hair shaft generation and hair matrix keratinocyte proliferation, suggesting potential anagen-prolonging effects.
36 citations
,
October 2016 in “Bone” This case report describes a male patient with aromatase deficiency, revealing that a c.628G>A mutation can lead to varied clinical features, such as low bone mass and normal metabolic profiles.
35 citations
,
January 2014 in “Postepy Dermatologii I Alergologii” This study found that increased dihydrotestosterone levels were observed in both androgenetic alopecia patients and controls, suggesting that follicle sensitivity to DHT may be more critical than DHT levels for alopecia development.
34 citations
,
April 2007 in “Neuroscience” In this study, finasteride altered acute ethanol withdrawal severity differently in male and female mice, highlighting sex differences in sensitivity to changes in neurosteroid levels.
33 citations
,
December 2015 in “Neuroendocrinology” This study found that subchronic finasteride treatment in male rats altered neuroactive steroid levels and steroid receptor expression in the brain, with some changes persisting after drug withdrawal.
32 citations
,
September 2018 in “Clinical Obstetrics and Gynecology” This article states that hormone therapy with estrogens and antiandrogens for transgender females is within an obstetrician-gynecologist's practice scope and involves careful dosing and monitoring to manage short-term thrombotic risks.
32 citations
,
December 1999 in “Journal of Investigative Dermatology Symposium Proceedings” This study found that the effectiveness of 17-beta-estradiol in inhibiting hair growth depends on its application method, and noted significant sex differences in response to 17-alpha-estradiol in male and female mice.
31 citations
,
January 2003 in “Dermatology” This article provides an overview of recent discoveries about steroidogenic enzymes involved in androgenetic alopecia but reports no new clinical results.
31 citations
,
September 2006 in “The Journal of Clinical Endocrinology & Metabolism” This article discusses the development of a transdermal testosterone patch for postmenopausal women to deliver physiological testosterone levels but reports no new clinical results, highlighting a need for long-term safety data.
30 citations
,
April 2007 in “Dermatologic Clinics” This review discusses the mechanisms by which isotretinoin and hormonal therapy treat acne through their effects on sebaceous glands, reporting no new clinical results.
29 citations
,
January 2006 in “Clinical chemistry and laboratory medicine” This study found that male liver cirrhosis patients have higher estradiol levels and lower dehydroepiandrosterone sulfate, leading to hormonal imbalances favoring estradiol, but without changing sex hormone-binding globulin's binding properties.
27 citations
,
April 2013 in “Reviews in endocrine and metabolic disorders” The document concludes that using LC-MS/MS for measuring androgens is more accurate than older methods, but it needs careful validation and standardized references to be most effective.
26 citations
,
May 2012 in “Cellular and Molecular Life Sciences” This review discusses the structure, expression, regulation, and potential roles of NcoA4 in cancer and other pathologies, reporting no new experimental findings.
25 citations
,
May 2003 in “Expert Opinion on Therapeutic Patents” This review examines patents and publications on steroid sulfatase inhibitors since 1999 and reports no new clinical results, highlighting their potential for treating estrogen- and androgen-driven conditions.
24 citations
,
May 2015 in “Schizophrenia Research” This study found that inhibiting the enzyme 5α-reductase with finasteride counteracted stress-induced prepulse inhibition deficits in socially isolated rats by altering neuroactive steroid concentrations in the brain.
24 citations
,
January 2001 in “Dermatologic clinics” This article reviews the use of hormonal therapies in dermatology, specifically focusing on their pathophysiologic rationale, indications, commonly used drugs, and pretreatment evaluations, and it reports no new research findings.
22 citations
,
November 2018 in “Breast Cancer Research and Treatment” In this review, researchers found no evidence of interactions between 5α-reductase inhibitors or spironolactone and endocrine therapies for breast cancer, with no consistent changes in estrogen levels or increased breast cancer risk associated with spironolactone usage.
22 citations
,
January 2004 in “Dermatology” This article discusses the use of topical estrogen therapy for androgenetic alopecia in menopausal females and reports no new clinical results.
21 citations
,
January 2003 in “Skin pharmacology and physiology” This study found that dutasteride completely suppressed the formation of 5alpha-dihydro metabolites in cultured human skin cells, suggesting its potential use in acne and androgenetic alopecia.
19 citations
,
January 1997 in “Dermatologic Clinics” This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.
18 citations
,
February 2016 in “The Journal of Clinical Endocrinology and Metabolism” This article reviews emerging opportunities and challenges in male reproductive medicine, including advancements and unmet needs in erectile dysfunction, androgen deficiency, and fertility, but reports no new clinical findings.
18 citations
,
October 2010 in “Bioorganic & Medicinal Chemistry Letters” This study found that a new hybrid compound designed from finasteride and epristeride was a potent inhibitor of 5α-reductase with a mechanism similar to finasteride.
15 citations
,
October 2011 in “Gynecological Endocrinology” This study found that obesity in PCOS women with biochemical hyperandrogenemia lowers androstenedione levels and increases the testosterone to androstenedione ratio, but this was not observed in women with clinical hyperandrogenemia or in controls.
14 citations
,
January 2018 in “Advances in Clinical Chemistry” This review discusses the evaluation of hyperandrogenemia in women and hypogonadism in men across different life stages and presents biomarkers used for diagnosing male hypogonadism, reporting no new clinical results.